

Resource Summary Report

Generated by [RRID](#) on Aug 31, 2026

AM-38

RRID:CVCL_1070

Type: Cell Line

Proper Citation

RRID:CVCL_1070

Cell Line Information

URL: https://web.expasy.org/cellosaurus/CVCL_1070

Proper Citation: RRID:CVCL_1070

Description: Cell line AM-38 is a Cancer cell line with a species of origin Homo sapiens (Human)

Sex: Male

Disease: Glioblastoma

Defining Citation: [PMID:7947440](#), [PMID:8145054](#), [PMID:12068308](#), [PMID:16232199](#), [PMID:20164919](#), [PMID:22460905](#), [PMID:25877200](#), [PMID:25984343](#), [PMID:26589293](#), [PMID:27397505](#), [PMID:30894373](#), [PMID:30971826](#), [PMID:31068700](#), [PMID:35839778](#)

Comments: Population: Japanese., Part of: COSMIC cell lines project., Part of: Cancer Dependency Map project (DepMap) (includes Cancer Cell Line Encyclopedia - CCLE).

Category: Cancer cell line

Organism: Homo sapiens (Human)

Name: AM-38

Synonyms: AM38, AM

Cross References: CLO:CLO_0009880, ArrayExpress:E-MTAB-783, ArrayExpress:E-MTAB-2770, ArrayExpress:E-MTAB-3610, BioGRID_ORCS_Cell_line:829, BioSample:SAMN03470932, BioSample:SAMN10987853, cancercellines:CVCL_1070, Cell_Model_Passport:SIDM00492, CGH-DB:139-1, ChEMBL-Cells:ChEMBL3308829, ChEMBL-Targets:ChEMBL2366192, Cosmic:685873, Cosmic:910933, Cosmic:1746962, Cosmic:2302334, Cosmic:2367507, Cosmic:2516013, Cosmic-CLP:910933, DepMap:ACH-000269, EGA:EGAS00001000978, GDSC:910933, GEO:GSM326247, GEO:GSM886866, GEO:GSM887931, GEO:GSM1669598, IARC_TP53:21174,

JCRB:IFO50492, LiGeA:CCLE_669, LINCS_LDP:LCL-1366,
PharmacoDB:AM38_60_2019, PRIDE:PXD030304, Progenetix:CVCL_1070,
PubChem_Cell_line:CVCL_1070, Wikidata:Q54749551

ID: CVCL_1070

Record Creation Time: 20220427T215218+0000

Record Last Update: 20260830T002227+0000

Ratings and Alerts

No rating or validation information has been found for AM-38.

No alerts have been found for AM-38.

Data and Source Information

Source: [Cellosaurus](#)

Usage and Citation Metrics

We found 7 mentions in open access literature.

Listed below are recent publications. The full list is available at [RRID](#) .

Cornelissen FMG, et al. (2025) Combined Inactivation of MEK and mTOR Can Lead to Synergistic Cell Death in Glioblastoma Models and Associates with NF1 Deficiency and a Mesenchymal Subtype. *Molecular cancer therapeutics*, 24(12), 1878.

Hayashi T, et al. (2024) Intraoperative Integrated Diagnostic System for Malignant Central Nervous System Tumors. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(1), 116.

Habashy KJ, et al. (2024) Paclitaxel and Carboplatin in Combination with Low-intensity Pulsed Ultrasound for Glioblastoma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 30(8), 1619.

Constantin D, et al. (2024) MR1 Gene and Protein Expression Are Enhanced by Inhibition of the Extracellular Signal-Regulated Kinase ERK. *Cancer immunology research*, 12(10), 1452.

Schreck KC, et al. (2021) Deconvoluting Mechanisms of Acquired Resistance to RAF Inhibitors in BRAFV600E-Mutant Human Glioma. *Clinical cancer research : an official journal of the American Association for Cancer Research*, 27(22), 6197.

Zahedi S, et al. (2019) Effect of early-stage autophagy inhibition in BRAFV600E autophagy-dependent brain tumor cells. *Cell death & disease*, 10(9), 679.

Mulcahy Levy JM, et al. (2017) Autophagy inhibition overcomes multiple mechanisms of resistance to BRAF inhibition in brain tumors. *eLife*, 6.